Recent research have focused on the intersection of GLP-1|GIP|glucagon receptor activator therapies and DA communication. While GCGR agonists are commonly employed for addressing type 2 diabetes mellitus, their potential effects on reinforcement circuits, specifically influenced by dopaminergic pathways, are attracting substantial focus. This re… Read More